Novo Nordisk raised its full-year sales and operating profit outlook as Wegovy pill demand strengthened, improving the growth picture despite continued pricing pressure.
Read the full research in the app
A subscription is required to access the full thread.
Open in the app →Financials
Technicals
Earnings-peers